Failure of adjunctive cytomegalovirus intravenous immune globulin to improve efficacy of ganciclovir in patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis: a phase 1 study.
Six men with acquired immunodeficiency syndrome (AIDS) and cytomegalovirus (CMV) retinitis, treated with combined ganciclovir induction therapy and hyperimmune globulin (CMV-IGIV) for 10 days followed by CMV-IGIV alone, had a median time to retinitis progression shorter (7 days) than had eight historical controls given ganciclovir maintenance therapy (54 days; P = 0.06) and similar to that in eight controls given ganciclovir for 10 days only (19 days; P = 0.97). CMV-IGIV, which also failed to inhibit CMV replication in blood and urine, did not appear to add markedly to the efficacy of ganciclovir in acquired immunodeficiency syndrome-associated CMV retinitis.
Jacobson
M A
MA
Medical Service, San Francisco General Hospital, California 94110.
O'Donnell
J J
JJ
Rousell
R
R
Dionian
B
B
Mills
J
J
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications / Q000628:therapy*; D000328:Adult; D003587:Cytomegalovirus / Q000276:immunology*; D003586:Cytomegalovirus Infections / Q000150:complications / Q000628:therapy*; D015774:Ganciclovir / Q000009:adverse effects / Q000627:therapeutic use*; D005916:Globulins / Q000009:adverse effects / Q000276:immunology*; D006801:Humans; D008297:Male; D012173:Retinitis / Q000150:complications / Q000628:therapy*
D005916:Globulins; D015774:Ganciclovir